ArticleCureus2025
Clinicopathologic Analysis of Granuloma Annulare With Insights Into Its Incidence and Demographics in the United Arab Emirates From 2016 to 2023.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploratory evaluation of local hyperthermia (44 ± 2 °C) in granuloma annulare: A pilot randomized controlled study.JAAD international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granuloma annulare (GA) is a benign, often chronic dermatologic condition with varying clinical presentations and has been associated in the literature with a notable psychosocial burden, particularly in generalized cases. This retrospective cross-sectional study analyzed the epidemiological and clinicopathological features of GA and its variants in the United Arab Emirates (UAE) from 2016 to 2023. A total of 171 histopathologically confirmed GA cases were included, collected from a single dermatopathology center. The incidence of GA diagnoses showed temporal variation, peaking in 2020 at 0.67% (n = 27) and declining significantly to 0.27% (n = 20) by 2023, as confirmed by a two-proportion z-test (z = 3.24, p = 0.001). However, no significant monotonic trend was observed across the full eight-year period (ρ = -0.19, p = 0.65). Localized GA emerged as the predominant subtype (n = 118, 69.0%), with a marked female predominance across the cohort. The mean age of patients was 39.49 ± 13.87 years, and middle-aged adults (36-55 years) constituted the largest age group (n = 82, 48%). A chi-square goodness-of-fit test demonstrated a statistically significant difference in the distribution of GA variants (χ²(3, N = 171) = 186.54, p < 0.001), with interstitial, papular, and deep GA occurring less frequently than expected. Lesions most frequently involved the upper and lower limbs. While age distribution across GA subtypes did not show a statistically significant association (χ²(12, N = 171) = 13.62, p = 0.326), demographic patterns revealed a richly diverse patient population representing over 35 nationalities, with British and Emirati individuals comprising a notable portion. These findings contribute meaningful insight into the epidemiology and clinicopathology of GA in a multicultural setting and offer a foundation for further exploration into immunologic and genetic factors that could drive precision-based treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.